Please login to the form below

Not currently logged in
Email:
Password:

ECJ Opinion supports ABPI

General Jaaskinen supports ABPI's claim that the MHRA prescribing incentive schemes to clinicians is prohibited under European law

An Opinion from the European Court of Justice (ECJ) has supported the Association of the British Pharmaceutical Industry (ABPI) in its claims against the Medicines and Healthcare products Regulatory Agency (MHRA) that prescribing incentive schemes operated by Primary Care Trusts (PCTs) are in fact prohibited under Article 94(1) of European Directive 2001/83.

The Opinion, delivered on February 11, 2010 by Advocate General Jaaskinen, concluded that prescribing incentive schemes, which promote medicines by offering financial incentives to doctors currently prescribing or intending to prescribe specifically named medicine 'A', to start prescribing specifically named medicine 'B', are unlawful. 

Advocate General Jaaskinen continued that the rules on promotion of medicines in Directive 2001/83 apply not just to commercial bodies, but also to public authorities, including PCTs  and that 'promotion' had occurred in these schemes as they "have the deliberate and direct intention of promoting within the NHS certain medicines at the expense of others". 

He said the fact that the aim was to save budgetary resources and improve the provision of public health services is irrelevant, and exemptions did not apply.

While an Opinion is not the final stage in litigation, it plays a part in assisting the full court form its final judgement, which is likely to be in the next three to six months.

15th February 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...